Lung Cancer: Iressa submitted for approval in Europe

Astra Zeneca’s anti lung cancer drug; Iressa, is a candidate for approval in Europe, for the treatment of non small cell lung cancer locally advanced or metastatic.

Approval of this drug in the U.S. is pending FDA action, which is expected soon.

Webmaster

June 02, 2003